← Back to patent-cliff list
STC-004
Tier C — Watch / tradeSTC-004
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Nav1.8
Indications (approved)：Pain, 神经痛, Postoperative pain, 急性疼痛, Chronic pain
Regional status
US
-
2023-05-19
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of STC-004?
Approved indications include: Pain, 神经痛, Postoperative pain, 急性疼痛, Chronic pain.
When does the STC-004 patent expire?
No public expiry year is available for STC-004 yet; this page updates once verified.
How do I get a quote for STC-004 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30